microRNA 1269a (miR-1269a)

microRNA 1269a (miR-1269a) is a short, non-coding RNA located on human chromosome 4, acting as a post-transcriptional regulator of gene expression. It sequences and silences several downstream targets, including SOX6, FOXO1, ATRX, and others, by binding to their mRNA and suppressing translation. miR-1269a is frequently overexpressed in multiple human cancers (including hepatocellular, lung, esophageal, glioma, and gastric cancers). Its elevated expression is associated with increased cell proliferation, migration, invasion, inhibition of apoptosis, and poor prognosis. Pathways regulated by miR-1269a include TGF-β, PI3K/AKT, and p53, all of which play critical roles in tumorigenesis, metastasis, and resistance to therapy. A specific single nucleotide polymorphism (rs73239138) within miR-1269a is associated with decreased cancer risk and increased apoptosis, making it a proposed biomarker and therapeutic target. miR-1269a is regulated by competing endogenous RNAs including lncRNAs and circRNAs, which modulate its activity and contribute to a complex regulatory network in cancer biology. While no approved drugs yet target miR-1269a directly, it remains an active area of research, especially for RNA-based therapeutics aimed at modulating its expression in cancer and overcoming chemoresistance.

Other names

hsa-mir-1269aMIR1269AMIR1269microRNA 1269MIRN1269hsa-mir-1269

Drugs or therapeutic strategies may act by inhibiting miR-1269a (using antagomirs, locked nucleic acids, or similar RNA therapeutics) to restore the function of tumor suppressor genes or promote apoptosis. Chemoresistance modulation (miR-1269a SNP associated with chemotherapy outcomes).